Sagent announces the launch of its levoflaxcin injection

Sagent Pharmaceuticals, Inc., recently announced the launch of its levoflaxcin injection, the generic form of the antibiotic Levaquin, a fluoroquinolone antibacterial for use against post-exposure anthrax, in three ready-to-use premix strengths.

Levoflaxcin was approved by the FDA at the end of June to treat certain infections, including inhalational anthrax. The oral solution, generic tablet and injectable solution dosage forms of levofloxacin have been approved under 12 manufacturer’s applications.

The U.S. market for levoflaxcin, indicated in adults over the age of 18 with infections caused by bacteria including anthrax, pneumonia, chronic bronchitis, urinary tract infections and prostatitis, is estimated to be $156 million, according to

"As with other products in our anti-infective portfolio, levofloxacin injection is widely used because of its efficacy on wide variety of bacterial infections,” Jeffrey M. Yordon, chief executive officer of Sagent, said, GlobeNewsWire reports. “In addition, our premix, ready-to-use levofloxacin injection offering features our PreventIV Measures packaging and labeling, designed to aid in the reduction of medication errors.”

Levoflaxin has not been tested in humans for post-exposure prevention of inhalation anthrax.

Sagent specializes in injectionable products known for their efficacy against a wide variety of bacterial infections.

Inhalation anthrax infection is currently treated with a 60 day course of antibiotics, according to the Centers for Disease Control and Prevention.